Back to results

Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

X. Pivot, et al. Annals of Oncology, 25, 1979–1987 (2014)

Please Signup/Login to see the full article.